Sutro Biopharma STRO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.52M+24.7% | $11.65M+20.2% | $9.69M-84.8% | $63.75M+266% | $17.4M+17.5% | ||
| $36.55M-0.2% | $36.64M-8.1% | $39.85M+4.0% | $38.33M-25.7% | $51.6M-27.4% | ||
| $7.58M-12.4% | $8.66M-0.9% | $8.74M-15.5% | $10.34M-22.1% | $13.27M+47.0% | ||
| $44.18M-11.1% | $49.7M-14.5% | $58.15M-13.3% | $67.09M-21.9% | $85.91M+7.3% | ||
| -$29.66M+22.1% | -$38.05M+21.5% | -$48.46M-1,349% | -$3.35M+95.1% | -$68.51M-5.0% | ||
| -204.2%+122pp | -326.7%+173pp | -499.9%-495pp | -5.2%+389pp | -393.8%+46.9pp | ||
| -$38.5M+17.8% | -$46.84M+17.6% | -$56.86M-394% | -$11.52M+84.8% | -$75.96M-8.4% | ||
| -$15K+81.7% | -$82K— | $0+100% | -$18K-357% | $7K-99.7% | ||
| -$38.48M+17.7% | -$46.76M+17.8% | -$56.86M-394% | -$11.5M+84.9% | -$75.97M-4.9% | ||
| -265%+137pp | -401.5%+185pp | -586.6%-569pp | -18%+419pp | -436.6%+52.6pp | ||
| -$2.94+85.9% | -$20.78-3,001% | -$0.67-379% | -$0.14+98.5% | -$9.08+66.8% | ||
| -$28.38M+22.1% | -$36.43M+21.8% | -$46.56M-3,122% | -$1.45M+97.8% | -$66.61M-5.1% | ||
| -195.4%+117pp | -312.7%+168pp | -480.3%-478pp | -2.3%+381pp | -382.9%+45.2pp | ||
| -$29.66M+22.1% | -$38.05M+21.5% | -$48.46M-1,349% | -$3.35M+95.1% | -$68.51M-5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $99.6M in revenue over the trailing twelve months, up 49.9% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $153.6M over the trailing twelve months, a -154.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-24.53.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
